申请人:Roche Diagnostics GmbH
公开号:EP1216994A2
公开(公告)日:2002-06-26
The present invention is directed to novel tricyclic antidepressant drug derivatives synthesized for covalent attachment to proteins or polypeptide antigens for use in the preparation of antibodies or receptors to tricyclic antidepressant drugs and tricyclic antidepressant metabolites. The new derivatives are characterized by a saturated double bond on the amitriptyline portion of the molecule and are represented by the structure
where R1 is a saturated or unsaturated, substituted or unsubstituted, straight or branched chain of 0-10 carbon or heteroatoms, X is a linker group consisting of 0-2 substituted or unsubstituted aromatic rings, and Y is an activated ester or NH-Z, where Z is a poly(amino acid).
The novel tricyclic antidepressant activated hapten derivatives are useful for preparing tracers and conjugates for tricyclic antidepressant immunoassays, including an enzyme immunoassay and a microparticle capture inhibition assay using an antibody produced from the novel immunogen with a conjugate derivatized either at the N-1 position of imipramine or at the C-2 position of dihydroamitriptyline.
本发明是针对新型三环类抗抑郁药物衍生物的合成,该衍生物可与蛋白质或多肽抗原共价连接,用于制备三环类抗抑郁药物和三环类抗抑郁药物代谢物的抗体或受体。新衍生物的特点是分子中的阿米替林部分具有饱和双键,其结构如下
其中 R1 是 0-10 个碳原子或杂原子的饱和或不饱和、取代或未取代的直链或支链,X 是由 0-2 个取代或未取代的芳香环组成的连接基团,Y 是活化酯或 NH-Z,其中 Z 是多(氨基酸)。
新型三环类抗抑郁药活化合体衍生物可用于制备三环类抗抑郁药免疫测定的示踪剂和共轭物,包括酶免疫测定和微粒子捕获抑制测定,使用的抗体由新型免疫原与在丙咪嗪的 N-1 位或双氢阿米替林的 C-2 位衍生的共轭物产生。